Mizuho Maintains Buy on Harmony Biosciences, Maintains $54 Price Target
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh has maintained a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) and kept the price target at $54.
September 19, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho has maintained a 'Buy' rating on Harmony Biosciences, indicating positive sentiment towards the stock. The price target remains at $54.
Analyst ratings often influence the short-term price movement of stocks. A maintained 'Buy' rating indicates that the analyst continues to have a positive outlook on the stock, which could lead to increased investor confidence and potentially a rise in the stock price. The maintained price target of $54 also suggests that the analyst believes the stock has potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100